Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality

Bibliographic Details
Main Authors:	Lixin Du, Jiao Qin, Dengchuan Wang, Yunhui Zhao, Ning Xu, Chaowen Wu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	cardiovascular renal death type 2 diabetes SGLT 2 inhibitors GLP-1RAs
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2022.987025/full

Similar Items

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
by: Mei Qiu, et al.
Published: (2021-12-01)

Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status
by: Lixin Du, et al.
Published: (2022-09-01)

Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
by: Lixin Du, et al.
Published: (2022-11-01)

GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway
by: Alessio Mazzieri, et al.
Published: (2023-11-01)

GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis
by: Hongle Yan, et al.
Published: (2022-07-01)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
by: Dario Giugliano, et al.
Published: (2021-10-01)

Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
by: Katarzyna Wołos-Kłosowicz, et al.
Published: (2022-10-01)

Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance
by: Angelica Cersosimo, et al.
Published: (2024-03-01)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
by: Apurva Khedagi, et al.
Published: (2023-03-01)

SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study
by: Zheer Kejlberg Al-Mashhadi, et al.
Published: (2022-08-01)

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
by: Lixin Du, et al.
Published: (2022-10-01)

The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure
by: Peng‐juan Ji, et al.
Published: (2023-04-01)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
by: Bartosz Rolek, et al.
Published: (2023-07-01)

HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity
by: P.P. Mohanan, et al.
Published: (2023-01-01)

Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
by: Heeyoung Lee, et al.
Published: (2021-09-01)

High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination
by: Marvin Wei Jie Chua
Published: (2021-12-01)

Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence
by: Dion R. P. Muller, et al.
Published: (2023-10-01)

The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus
by: Teodor Salmen, et al.
Published: (2023-03-01)

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
by: Magdalena Złotek, et al.
Published: (2023-11-01)

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
by: Panagiotis I. Georgianos, et al.
Published: (2022-02-01)

Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
by: Martina Belli, et al.
Published: (2022-11-01)

Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study
by: Omar Dzaye, et al.
Published: (2022-07-01)

GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes
by: Raffaele Marfella, et al.
Published: (2024-01-01)

Phytomedicine as a source of SGLT2 inhibitors, GLP-1 secretagogues and DPP-IV inhibitors for mitigation of Diabetic Nephropathy
by: Anuj Kumar Borah, et al.
Published: (2022-05-01)

Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
by: Masao Koike, et al.
Published: (2021-10-01)

The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review
by: Ioanna Daniilopoulou, et al.
Published: (2022-02-01)

Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease
by: Yaofu Zhang, et al.
Published: (2022-11-01)

SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
by: Gurgle HE, et al.
Published: (2016-06-01)

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
by: Chudleigh RA, et al.
Published: (2020-02-01)

Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
by: Takayuki Yamada, et al.
Published: (2021-01-01)

The Impact of GLP-1 RAs and DPP-4is on Hospitalisation and Mortality in the COVID-19 Era: A Two-Year Observational Study
by: Salvatore Greco, et al.
Published: (2023-08-01)

Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
by: Yolanda Diz-Chaves, et al.
Published: (2022-08-01)

Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes
by: André J. Scheen
Published: (2024-01-01)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
by: Dario Giugliano, et al.
Published: (2022-03-01)

Anti-Inflammatory Effects of GLP-1R Activation in the Retina
by: Alessandra Puddu, et al.
Published: (2022-10-01)

Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis
by: Hong Li, et al.
Published: (2024-02-01)

Comparative Study of the Effects of GLP1 Analog and SGLT2 Inhibitor against Diabetic Cardiomyopathy in Type 2 Diabetic Rats: Possible Underlying Mechanisms
by: Abdelaziz M. Hussein, et al.
Published: (2020-02-01)

Role of metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) receptor agonists, and orlistat based multidrug therapy in glycemic control, weight loss, and euglycemia in diabesity: A real-world experience
by: Deep Dutta, et al.
Published: (2019-01-01)

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
by: Lucia Scisciola, et al.
Published: (2023-02-01)

Glucagon-Like Peptide-2 and the Enteric Nervous System Are Components of Cell-Cell Communication Pathway Regulating Intestinal Na+/Glucose Co-transport
by: Andrew W. Moran, et al.
Published: (2018-10-01)